A critical review of gastric retentive controlled drug delivery

Pharmaceutical Development and Technology

Volumn 12, Issue 1, 2007, Pages 1-10

  Waterman, Kenneth C ^a  

^a PFIZER INC   (United States)

Author keywords

Controlled release; Drug absorption; Drug delivery; Expanding dosage; Floating drug delivery; Gastric retention; Hydrodynamically balanced system; Mucoadhesion

Indexed keywords

ALGINIC ACID; AMOXICILLIN; CARBOMER; CHITOSAN; COLESTYRAMINE; DILTIAZEM; FUROSEMIDE; GENTAMICIN; ISRADIPINE; MISOPROSTOL; OFLOXACIN; PARACETAMOL; POLACRILIN; POLYCARBOPHIL; RIBOFLAVIN; SALBUTAMOL; THEOPHYLLINE; VERAPAMIL;

CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG DOSAGE FORM; DRUG RETENTION; HUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; METABOLISM; STOMACH;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; HUMANS; STOMACH;

EID: 34249677860     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450601168680     Document Type: Review

References (70)

1. Moës, A.J. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 1993, 10, 143-195.
2. Deshpande, A.A.; Rhodes, C.T.; Shah, N.H.; Malick, A.W. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev. Ind. Pharm. 1996, 22 (6), 531-539.
3. Hwang, S.-J.; Park, H.; Park, K. Gastric retentive drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 1998, 15 (3), 243-284.
4. Singh, B.N.; Kim, K.H. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J. Control. Release 2000, 63, 235-259.
5. Fell, J.T.; Whitehead, L.; Collett, J.H. Prolonged gastric retention using floating dosage forms. Pharm. Tech. 2000 March, 82, 84, 86, 88, 90.
6. Soppimath, K.S.; Kulkarni, A.R.; Rudzinski, W.E.; Aminabhavi, T.M. Microspheres as floating drug-delivery systems to increase gastric retention of drugs. Drug Met. Rev. 2001, 33, 149-160.
7. Gutierrez-Rocca, J.; Omidian, H.; Shah, K. Progress in gastroretentive drug delivery systems. Business Briefing: Pharmatech. 2003, 152-156.
8. Hou, S.Y.E.; Cowles, V.E.; Berner, B. Gastric retentive dosage forms: a review. Crit. Rev. Ther. Drug Carrier Syst. 2003, 20, 461-497.
9. Klausner, E.A.; Lavy, E.; Friedman, M.; Hoffman, A. Expandable gastroretentive dosage forms. J. Control. Release 2003, 90 (2), 143-162.
10. Moës, A.J. Gastric retention systems for oral drug delivery. Business Briefing: Pharmatech. 2003, 157-159.
11. Talukder, R.; Fasshihi, R. Gastroretentive delivery systems: A mini review. Drug Dev. Ind. Pharm. 2004, 30, 1019-1028.
12. Hoffman, A.; Stepensky, D.; Lavy, E.; Eyal, S.; Klausner, E.; Friedman, M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms, Int. J. Pharm. 2004, 277 (1-2), 141-153.
13. Chowdary, K.P.R.; Rao, Y.S. Mucoadhesive microspheres and microcapsules: Current status. Ind. J. Pharm. Sci. 2005, 67, 141-150.
14. Rocca, J.G.; Omidian, H.; Shah, K.U. Commercial status of gastric retention technologies. Drug Del. Tech. 2005, 50-58.
15. Bardonnet, P.L.; Faivre, V.; Pugh, W.J.; Piffaretti, J.C.; Falson, F. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J. Control. Release 2006, 111 (1-2), 1-18.
16. Streubel, A.; Siepmann, J.; Bodmeier, R. Gastroretentive drug delivery systems. Expert Opin. Drug Deliv. 2006, 3 (2), 217-233.
17. Fix, J.A.; Cargill, R.; Engle, K. Controlled gastric emptying. III. Gastric residence time of a nondisintegrating geometric shape in human volunteers. Pharm. Res. 1993, 10, 1087-1089.
18. Coupe, A.J.; Davis, S.S.; Evans, D.F.; Wilding, I.R. Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility. Pharm. Res. 1991, 8 (10), 1281-1285.
19. Itoh, T.; Higuchi, T.; Gardner, C.R.; Caldwell, L. Effect of particle size and food on gastric residence time of non-disintegrating solids in beagle dogs. J. Pharm. Pharmacol. 1986, 38 (11), 801-806.
20. Kaniwa, N.; Aoyagi, N.; Ogata, H.; Ejima, A. Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates. J. Pharm.-Dyn. 1988, 11 (8), 563-570.
21. Nause, R.; Li, F.; Sagawa, K. Modeling and prediction of upper GI transit times for non-disintegrating oral dosage forms, Manuscript in preparation.
22. Davis, S.S.; Hardy, J.G.; Fara, J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986, 27 (8), 886-892.
23. Ewe, K.; Press, A.G.; Bollen, S.; Schuhn, I. Gastric emptying of indigestigle tablets in relation to composition and time of ingestion of meals studied by metal detector. Dig. Dis. Sci. 1991, 36 (2), 146-152.
24. Steed, K.P.; Hooper, G.; Monti, N.; Strolin Benedetti, M.; Fornasini, G.; Wilding, I.R. The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system ("TIME CLOCK" system). J. Control. Release 1997, 49 (2,3), 115-122.
25. Khosla, R.; Davis, S.S. The effect of polycarbophil on the gastric emptying of pellets. J. Pharm. Pharmacol. 1987, 39, 47-49.
26. Harris, D.; Fell, J.T.; Sharma, H.L.; Taylor, D.C. Gastrointestinal transit of potential bioadhesive formulations in man: A scintigraphic study, J. Control. Release 1990, 12, 45-53.
27. Jackson, S.J.; Bush, D.; Perkins, A.C. Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. Int. J. Pharm. 2001, 212, 55-62.
28. Säkkinen, M.; Tuononen, T.; Jürjenson, H.; Veski, P.; Marvola, M. Evaluation of microcrystalline chitosans for gastro-retentive drug delivery. Eur. J. Pharm. Sci. 2003, 19, 345-353.
29. Säkkinen, M.; Marvola, J.; Kanerva, H.; Lindevall, K.; Lipponen, M.; Kekki, T.; Ahonen, A.; Marvola, M. Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach. Eur. J. Pharm. Biopharm. 2004, 57, 133-143.
30. Ch'ng, H. S.; Park, H.; Kelly, P.; Robinson, J.R. Bioadhesive polymers as platforms for oral controlled drug delivery. II. Synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J. Pharm. Sci. 1985, 74 (4), 399-405.
31. Lehr, C.M.; Bouwstra, J.A.; Schacht, E.H.; Junginger, H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 1992, 78, 43-48.
32. He, P.; Davis, S.S.; Illum, L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int. J. Pharm. 1998, 166, 75-88.
33. Gåserød, O.; Jolliffe, A.G.; Hampson, F.C.; Dettmar, P.W.; Skjåk-Braek, G. The enhancement of the bioadhesive properties of calcium alginate gel beads by coating with chitosan. Int. J. Pharm. 1998, 175, 237-246.
34. Slovin, E.M.; Robinson, J.R. Bioadhesives in ocular drug delivery, Biopharm. Ocul. Drug Deliv. 1993, 145-157.
35. Signorin, J.; Aguinaldo, E.R.; Reilly, W.J. Nasal mucoadhesive characteristics of co-processed MCC CMC-Avicel RC-591. Proc. Intern. Symp. Control. Release Bioact. Mat. 1998, 25, 758-759.
36. Ugwoke, M.I.; Exaud, S.; Van Den Mooter, G.; Verbeke, N.; Kinget, R. Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. Eur. J. Pharm. Sci. 1999, 9, 213-219.
37. Ugwoke, M.I.; Verbeke, N.; Kinget, R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2001, 53, 3-22.
38. Jain, S.K.; Chourasia, M.K.; Jain, A.K.; Jain, R.K.; Shrivastava, A.K. Development and characterization of mucoadhesive microspheres bearing salbutamol for nasal delivery. Drug Deliv. 2004, 11 (2), 113-122.
39. Edsman, K.; Haegerstroem, H. Pharmaceutical applications of mucoadhesion for the non-oral routes. J. Pharm. Pharmacol. 2005, 57, 3-22.
40. Ingani, H.M.; Timmermans, J.; Moës, A. Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit. J. Int. Pharm. 1987, 35, 157-164.
41. Mazer, N.; Abisch, E.; Gfeller, J.-C.; Laplanche, R.; Bauerfeind, P.; Cucala, M.; Lukachich, M.; Blum, A. Intragastric behavior and absorption kinetics of a normal and "floating" modified-release capsule of isradipine under fasted and fed conditions. J. Pharm. Sci. 1988, 77, 647-657.
42. Washington, N.; Wilson, C.G.; Greaves, J.L.; Danneskiold-Samsøe, P. An investigation into the floating behaviour of a pectin-containing anti-reflux formulation (FF5005) by means of gamma scintigraphy, Scand. J. Gastroenterol. 1988, 23, 920-924.
43. Timmermans, J.; Van Gansbeke, B.; Moës, A.J. Assessing by gamma scintigraphy the in vivo buoyancy of dosage forms having known size and floating force profiles as a function of time. Congr. Int. Technol. Pharm. 5th 1989, 1, 42-51.
44. Timmermans, J.; Moës, A.J. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: New data for reconsidering the controversy. J. Pharm. Sci. 1994, 83 (1), 18-24.
45. Babu, V.B.M.; Khar, R.K. In vitro and in vivo studies of sustained-release floating dosage forms containing salbutamol sulfate. Pharmazie 1990, 45, 268-270.
46. Phuapradit, W.; Bolton, S. The influence of tablet density on the human oral absorption of sustained release acetaminophen tablets. Drug Dev. Ind. Pharm. 1991, 17, 1097-1107.
47. Xu, W.L.; Tu, X.D.; Lu, Z.D. Development of gentamicin sulfate sustained-release tablet floating in stomach. Yaoxue Xuebao 1991, 26 (7), 541-545.
48. Agyilirah, G.A.; Green, M.; DuCret, R.; Banker, G.S. Evaluation of the gastric retention properties of a crosslinked polymer coated tablet versus those of a nondisintegrating tablet. Int. J. Pharm. 1991, 75 (2-3), 241-247.
49. Hilton, A.K.; Deasy, P.B. In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxicillin trihydrate. Int. J. Pharm. 1992, 86, 79-88.
50. Oth, M.; Franz, M.; Timmermans, J.; Möes, A. The bilayer floating capsule: A stomach-directed drug delivery system for misoprostol. Pharm. Res. 1992, 9, 298-302.
51. Desai, S.; Bolton, S. A floating controlled-release drug delivery system: In vitro-in vivo evaluation. Pharm. Res. 1993, 10, 1321.
52. Özdemir, N.; Ordu, S.; Özkan, Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations. Drug Dev. Ind. Pharm. 2000, 26, 857-866.
53. Gabr, K.E.; Borg, T.M. Formulation and evaluation of buffered floating furosemide delivery systems. S.T.P. Pharm. Sci. 2000, 10, 181-186.
54. Chavanpatil, M.; Jain, P.; Chaudhari, S.; Shear, R.; Vavia, P. Development of sustained release gastroretentive drug delivery system for ofloxain: in vitro and in vivo evaluation. Int. J. Pharm. 2005, 304, 178-184.
55. Bechgaard, H. Distribution of different types of dosage forms in the gastrointestinal tract. Top. Pharm. Sci. 1983, 217-228.
56. Bechgaard, H.; Christensen, F.N.; Davis, S.S.; Hardy, J.G.; Taylor, M.J.; Whalley, D.R.; Wilson, C.G. Gastrointestinal transit of pellet systems in ileostomy subjects and the effect of density. J. Pharm. Pharmacol. 1985, 37, 718-721.
57. Lippold, B.C.; Günther, J. In-vivo Prüfung einer multipartikulären Retard-Schwimmarzneiform. Eur. J. Pharm. Biopharm. 1991, 37, 254-261.
58. Kawashima, Y.; Niwa, T.; Takeuchi, H.; Hino, T.; Ito, Y. Preparation of multiple unit hollow microspheres (microballoons) with acrylic resin containing tranilast and their drug release characteristics (in vitro) and floating behavior (in vivo). J. Control. Release 1991, 16, 279-190.
59. Atyabi, F.; Sharma, H.L.; Mohammad, H.A.H.; Fell, J.T. In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins. J. Control. Release 1996, 42, 105-113.
60. Iannuccelli, V.; Coppi, G.; Cameroni R. Intragastric behaviour of a multiple-unit dosage form. Proc. Intl. Symp. Control. Release Bioact. Mater. 1997, 24, 403-404.
61. Iannuccelli, V.; Coppi, G.; Sansone, R.; Ferolla, G. Air compartment multiple-unit system for prolonged gastric residence. II. In vivo evaluation. Int. J. Pharm. 1998, 174, 55-62.
62. Whitehead, L.; Fell, J.T.; Collett, J.H.; Sharma, H.L.; Smith, A.-M. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J. Control. Release 1998, 55, 3-12.
63. Sawicki, W. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. Eur. J. Pharm. Biopharm. 2002, 53, 29-35.
64. Shimpi, S.; Chauhan, B.; Mahadik, K.R.; Paradkar, A. Preparation and evaluation of diltiazem hydrochloride-gelucire 43/01 floating granules prepared by melt granulation. AAPS PharmSciTech 2004, 5, article 43 (hrrp://www.aapspharmscitech.org).
65. Munk, J.; Gannaway, R.; Hoare, M.; Johnson, A. In Gastroinestinal Motility in Health and Disease; Duthie, H.L. Ed.; MTP: Lancaster, 1978, 349-359.
66. Channer, K.S.; Virjee, J.P. The effect of size and shape of tablets on the esophageal transit. J. Clin. Pharmacol. 1986, 26, 141-146.
67. Gusler, G.; Gorsline, J.; Levy, G.; Zhang, S.Z.; Weston, I.E.; Naret, D.; Berner, B. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J. Clin. Pharmacol. 2001, 41, 655-661.
68. Gusler, G.; Berner, B. Metformin (GRTM) gastric retentive tablets: GI transit and pharmacokinetics in healthy volunteers. Millenial World Congress of Pharm. Sci.: San Francisco, 2000, 2-5019.
69. Klausner, E.A.; Lavy, E.; Barta, M.; Cserepes, E.; Friedman, M.; Hoffman, A. Novel gastroretentive dosage forms: Evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm. Res. 2003, 20, 1466-1473.
70. Cargill, R.; Caldwell, L.J.; Engle, K.; Fix, J.A.; Porter, P.A.; Gardner, C.R. Controlled gastric emptying. I. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs. Pharm. Res. 1988, 5, 533-536.